|
1
|
Gray LH, Conger AD, Ebert M, Hornsey S and
Scott OC: The concentration of oxygen dissolved in tissues at the
time of irradiation as a factor in radiotherapy. Br J Radiol.
26:638–648. 1953. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Moulder JE and Rockwell S: Tumor hypoxia:
Its impact on cancer therapy. Cancer Metastasis Rev. 5:313–341.
1987. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Holzer LA, Cör A, Pfandlsteiner G and
Holzer G: Expression of VEGF, its receptors and HIF-1α in
Dupuytren's disease. Acta Orthop. 84:420–425. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Brahimi-Horn MC, Chiche J and Pouyssegur
J: Hypoxia and cancer. J Mol Med (Berl). 85:1301–1307. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Vaupel P, Hockel M and Mayer A: Detection
and characterization of tumor hypoxia using pO2 histography.
Antioxid Redox Signal. 9:1221–1235. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Multhoff G, Radons J and Vaupel P:
Critical role of aberrant angiogenesis in the development of tumor
hypoxia and associated radioresistance. Cancers (Basel). 6:813–828.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ikeda E: Cellular response to tissue
hypoxia and its involvement in disease progression. Pathol Int.
55:603–610. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Salceda S and Caro J: Hypoxia-inducible
factor 1alpha (HIF-1alpha) protein is rapidly degraded by the
ubiquitin-proteasome system under normoxic conditions. Its
stabilization by hypoxia depends on redox-induced changes. J Biol
Chem. 272:22642–22647. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Semenza GL: Targeting HIF-1 for cancer
therapy. Nat Rev Cancer. 3:721–732. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Arjamaa O, Nikinmaa M, Salminen A and
Kaarniranta K: Regulatory role of HIF-1alpha in the pathogenesis of
age-related macular degeneration (AMD). Ageing Res Rev. 8:349–358.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang P, Zhang X, Hao X, Wang Y, Hui Y,
Wang H, Hu D and Zhou J: Rac1 activates HIF-1 in retinal pigment
epithelium cells under hypoxia. Graefes Arch Clin Exp Ophthalmol.
247:633–639. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Semenza GL: Regulation of mammalian O2
homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol.
15:551–578. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tammela T, Zarkada G, Nurmi H, Jakobsson
L, Heinolainen K, Tvorogov D, Zheng W, Franco CA, Murtomäki A,
Aranda E, et al: VEGFR-3 controls tip to stalk conversion at vessel
fusion sites by reinforcing Notch signalling. Nat Cell Biol.
13:1202–1213. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Semenza GL: HIF-1 and human disease: One
highly involved factor. Genes Dev. 14:1983–1991. 2000.PubMed/NCBI
|
|
15
|
Jain RK: Normalization of tumor
vasculature: An emerging concept in antiangiogenic therapy.
Science. 307:58–62. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ke QH, Zhou SQ, Huang M, Lei Y, Du W and
Yang JY: Early efficacy of Endostar combined with chemoradiotherapy
for advanced cervical cancers. Asian Pac J Cancer Prev. 13:923–926.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
O'Reilly MS, Boehm T, Shing Y, Fukai N,
Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR and Folkman J:
Endostatin: An endogenous inhibitor of angiogenesis and tumor
growth. Cell. 88:277–285. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Qi X, Liu Y, Wei W, Huang X and Zuo Y:
Effects of the C-terminal of endostatin on the tumorigenic
potential of H22 cells. Biomed Rep. 1:761–765. 2013.PubMed/NCBI
|
|
19
|
Huang RP and Adamson ED: A biological role
for Egr-1 in cell survival following ultra-violet irradiation.
Oncogene. 10:467–475. 1995.PubMed/NCBI
|
|
20
|
Zhang Y, Qiu W, Liang J, Yu Z and Yue L:
Anti-tumor effects of pEgr-1-endostatin-TNF-α recombinant plasmid
expression induced by ionizing radiation. Asian Pac J Cancer Prev.
12:2933–2937. 2011.PubMed/NCBI
|
|
21
|
El-Gendi S and Abdel-Hadi M: Lymphatic
vessel density as prognostic factor in breast carcinoma: Relation
to clinicopathologic parameters. J Egypt Natl Canc Inst.
21:139–149. 2009.PubMed/NCBI
|
|
22
|
Ferrara N and Davis-Smyth T: The biology
of vascular endothelial growth factor. Endocr Rev. 18:4–25. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cao D, Hou M, Guan YS, Jiang M, Yang Y and
Gou HF: Expression of HIF-1alpha and VEGF in colorectal cancer:
Association with clinical outcomes and prognostic implications. BMC
Cancer. 9:4322009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wilson WR and Hay MP: Targeting hypoxia in
cancer therapy. Nat Rev Cancer. 11:393–410. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li L, Huang JL, Liu QC, Wu PH, Liu RY,
Zeng YX and Huang WL: Endostatin gene therapy for liver cancer by a
recombinant adenovirus delivery. World J Gastroenterol.
10:1867–1871. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yoshimura M, Itasaka S, Harada H and
Hiraoka M: Microenvironment and radiation therapy. Biomed Res Int.
2013:6853082013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang J, Sun Y, Liu Y, Yu Q, Zhang Y, Li K,
Zhu Y, Zhou Q, Hou M, Guan Z, et al: Results of randomized,
multicenter, double-blind phase III trial of rh-endostatin (YH-16)
in treatment of advanced non-small cell lung cancer patients.
Zhongguo Fei Ai Za Zhi. 8:283–290. 2005.(In Chinese). PubMed/NCBI
|
|
28
|
Folkman J: Tumor angiogenesis: Therapeutic
implications. N Engl J Med. 285:1182–1186. 1971. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Forsythe JA, Jiang BH, Iyer NV, Agani F,
Leung SW, Koos RD and Semenza GL: Activation of vascular
endothelial growth factor gene transcription by hypoxia-inducible
factor 1. Mol Cell Biol. 16:4604–4613. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Brizel DM, Scully SP, Harrelson JM,
Layfield LJ, Bean JM, Prosnitz LR and Dewhirst MW: Tumor
oxygenation predicts for the likelihood of distant metastases in
human soft tissue sarcoma. Cancer Res. 56:941–943. 1996.PubMed/NCBI
|
|
31
|
Lohela M, Bry M, Tammela T and Alitalo K:
VEGFs and receptors involved in angiogenesis versus
lymphangiogenesis. Curr Opin Cell Biol. 21:154–165. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Mauceri HJ, Beckett MA, Liang H, Sutton
HG, Pitroda S, Galka E, Efimova E, Darga T, Khodarev NN, King CR,
et al: Translational strategies exploiting TNF-alpha that sensitize
tumors to radiation therapy. Cancer Gene Ther. 16:373–381. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kim YM, Jang JW, Lee OH, Yeon J, Choi EY,
Kim KW, Lee ST and Kwon YG: Endostatin inhibits endothelial and
tumor cellular invasion by blocking the activation and catalytic
activity of matrix metalloproteinase. Cancer Res. 60:5410–5413.
2000.PubMed/NCBI
|
|
34
|
Rehn M, Veikkola T, Kukk-Valdre E,
Nakamura H, Ilmonen M, Lombardo C, Pihlajaniemi T, Alitalo K and
Vuori K: Interaction of endostatin with integrins implicated in
angiogenesis. Proc Natl Acad Sci USA. 98:1024–1029. 2001.
View Article : Google Scholar : PubMed/NCBI
|
